Semaglutide and cardiovascular outcomes in obesity without diabetes

study052

10.1056/NEJMoa2307563

New England Journal of Medicine

randomized clinical trial

SELECT evaluated semaglutide for cardiovascular event reduction in adults with overweight or obesity without diabetes.

Semaglutide reduced major adverse cardiovascular events in this population.

semaglutide

cardiometabolic|fat-loss

metabolic-stack

semaglutide-vs-tirzepatide

published

‹ Semaglutide weight and anthropometric outcomes in obesity over long-term follow-up

Oral semaglutide 25 mg in adults with overweight or obesity ›